Arie Belldegrun, MD, FACS
Vice Chairman, Board of Directors
Chairman, Scientific Advisory Board
Cougar Biotechnology, Inc.
Chief, Division of Urologic Oncology
David Geffen School of Medicine at UCLA

Dr. Belldegrun joined Cougar Biotechnology, Inc. in December 2003 as Vice Chairman of the Board of Directors and Chairman of the Scientific Advisory Board. Dr. Belldegrun is Chief of the Division of Urologic Oncology and holds the Roy and Carol Doumani Chair in Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).

He is also the Founder of Agensys, Inc., a privately held biotechnology company focused on the development of fully human monoclonal antibodies to treat solid tumor cancers based on Agensys’ proprietary targets. Dr. Belldegrun served as founding Chairman of Agensys from 1997-2002 and currently serves on Agensys’ Board of Directors and as a consultant.

He completed his medical degree at the Hebrew University Hadassah Medical School in Jerusalem, his post graduate fellowship at the Weizmann Institute of Science and his residency in Urology at Harvard Medical School. Prior to UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH as a research fellow in surgical oncology under Steven A. Rosenberg, MD, PhD. He is certified by the American Board of Urology and a Fellow of the American College of Surgeons.

Dr Belldegrun is also on the scientific boards of several biotechnology and pharmaceutical companies and serves as a reviewer for many medical journals and granting organizations including the Journal of Urology and the American Foundation of Urologic Diseases. In addition to holding several patents, Dr. Belldegrun is the author of several books on prostate and kidney cancers and has written over 250 scientific publications with an emphasis on urologic oncology, particularly kidney, prostate and bladder cancers.

John P. Leonard, MD
Assistant Professor Of Medicine, Weill Medical College of Cornell University
Clinical Director, New York-Cornell Center for Lymphoma and Myeloma

John P. Leonard, M.D., is assistant professor of medicine at the Weill Medical College of Cornell University and clinical director of the New York – Cornell Center for Lymphoma and Myeloma. In addition, he is medical director of oncology services and assistant attending physician at the New York – Weill Cornell Center of New York Presbyterian Hospital. An expert in hematology and oncology, Dr. Leonard’s research has been published in numerous medical journals, and he is a member of the editorial board of the Journal of Clinical Oncology.

He serves as the non-Hodgkin’s lymphoma working group leader for the Lymphoma Committee of the Cancer and Leukemia Group B (CALGB), a multicenter cooperative group of the National Cancer Institute. His primary research interest is in the development of novel therapeutic strategies for the treatment of hematologic malignancies. Much of his work has involved the development of radiolabeled and unlabeled monoclonal antibodies as therapy for lymphoma, as well as immune-based and other novel therapies. Dr. Leonard performed his undergraduate work at Johns Hopkins University and received his medical degree at the University of Virginia School of Medicine in Charlottesville, VA.

He completed his residency in medicine at the New York Hospital - Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York, NY. He completed a fellowship in hematology and oncology at Cornell, and served as the chief medical resident at the New York Hospital - Cornell Medical Center.